
Ascletis Launches Global Phase III Trials for Oral Obesity Drug ASC30
Ascletis Pharma has secured FDA clearance to launch a global Phase III clinical program for ASC30, an oral small-molecule GLP-1 receptor agonist intended for chronic weight management. The study will enroll 4,600 participants across the U.S., Europe, and Canada, marking a significant step in the company’s bid to challenge injectable weight-loss therapies.


























